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Human ADSC xenograft through IL-6
secretion activates M2 macrophages
responsible for the repair of damaged
muscle tissue
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Abstract
Background: Adipose-derived mesenchymal stromal cells (ADSCs) are multipotent stromal cells. The cells secrete a
number of cytokines and growth factors and show immunoregulatory and proangiogenic properties. Their properties
may be used to repair damaged tissues. The aim of our work is to explain the muscle damage repair mechanism with the
utilization of the human adipose-derived mesenchymal stromal cells (hADSCs).
Methods: For the hADSCs isolation, we used the subcutaneous adipose tissue collected during the surgery. The murine
hind limb ischemia was used as a model. The unilateral femoral artery ligation was performed on 10–12-week-old male
C57BL/6NCrl and NOD SCID mice. The mice received PBS− (controls) or 1 × 106 hADSCs. One, 3, 7, 14 and 21 days after
the surgery, we collected the gastrocnemius muscles for the immunohistochemical analysis. The results were analyzed
with relevant tests using the Statistica software.
Results: The retention time of hADSCs in the limb lasted about 14 days. In the mice receiving hADSCs, the improvement
in the functionality of the damaged limb occurred faster than in the control mice. More new blood vessels were formed
in the limbs of the mice receiving hADSCs than in limbs of the control mice. hADSCs also increased the infiltration of the
macrophages with the M2 phenotype (7-AAD−/CD45+/F4/80+/CD206+) into the ischemic limbs. hADSCs introduced into
the limb of mice secreted interleukin-6. This cytokine stimulates the emergence of the proangiogenic M2 macrophages,
involved, among others, in the repair of a damaged tissue. Both macrophage depletion and IL-6 blockage suppressed the
therapeutic effect of hADSCs. In the mice treated with hADSCs and liposomes with clodronate (macrophages depletion),
the number of capillaries formed was lower than in the mice treated with hADSCs alone. Administration of hADSCs to
the mice that received siltuximab (human IL-6 blocker) did not cause an influx of the M2 macrophages, and the number
of capillaries formed was at the level of the control group, as in contrast to the mice that received only the hADSCs.
Conclusions: The proposed mechanism for the repair of the damaged muscle using hADSCs is based on the activity of
IL-6. In our opinion, the cytokine, secreted by the hADSCs, stimulates the M2 macrophages responsible for repairing
damaged muscle and forming new blood vessels.
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Background
The critical limb ischemia is an advanced stage of a per-
ipheral artery disease in which stenosis and occlusion of
the arteries occur. One of the methods of treatment for
this disease is therapeutic angiogenesis. The therapy uti-
lizes growth factors or cells that secrete factors which
stimulate the formation of new blood vessels [1–3]. An
increased number of blood vessels in the ischemic limb
model was observed after the administration of mesen-
chymal stromal cells isolated from the adipose tissue
(ADSC) [4].
ADSCs are multipotent stromal cells which secrete a
number of cytokines and growth factors and show im-
munoregulatory and proangiogenic properties. A domin-
ant cytokine secreted by ADSC is interleukin 6 (IL-6)
[5], which is a pleiotropic cytokine. This cytokine is in-
volved in the immune response and influences the for-
mation of new blood vessels by regulating the vascular
endothelial growth factor (VEGF) [6]. IL-6 is also one of
the cytokines participating in the process of the
polarization of the proinflammatory M1 macrophages
into the immunosuppressive, proangiogenic M2 macro-
phages [7, 8]. M2 macrophages are involved in the inhib-
ition of the inflammatory response, as in, they initiate
the tissue repair processes. They secrete and release
many proangiogenic factors (chemokines, cytokines,
growth factors) that stimulate endothelial cells to mi-
grate and proliferate [9].
Our results indicate that human adipose-derived mes-
enchymal stromal cells (hADSCs) introduced into the is-
chemic limb secrete interleukin 6. In our opinion, the
cytokine activates M2 macrophages responsible for the
formation of new blood vessels and eventually for the re-
pair of the damaged tissues.
Methods
Ethical statement
The experiments with animals were performed in ac-
cordance with the Declaration of Helsinki and with the
approval of the Local Ethics Committee for Animal Ex-
periments in Katowice (Permit Number: KB430-17/14).
Animals
Mice (8 to 10-week-old, C57Bl/6NCrl and NOD SCID,
males) were obtained from Charles River Breeding La-
boratories. All mice were housed in the Maria
Sklodowska-Curie Institute-Oncology Center, Gliwice
Branch (Poland) in a HEPA-filtered Allentown’s IVC Sys-
tem (Allentown Caging Equipment Co, NJ, USA). Mice
(n5) were kept in cages with an area of 435 cm2 and a
height of 13.3 cm (Allentown Caging Equipment Co).
The cage bed was a dust-free, resin-free, autoclavable
litter of aspen wood (MAXIÐLTE 004, ABEDD Vertriebs
GmbH, Wien, OÈ sterreich). The environment was
enriched with nesting materials of aspen wood fibers
with 2.5 mm (NBF E-011, Allentown Caging Equipment
Co). Mice were kept under 12-h dark/12-h light cycle in
SPF animal facility. The relative humidity in the
air-conditioned rooms was maintained at 50 ± 55% and
temperature at 21 ± 22ÊC. The animals received a total
pathogen-free standard diet (Altromin 1314, Altromin
Spezialfutter GmbH & Co. KG, Germany) and water ad
libitum throughout the whole study. This study was car-
ried out in strict accordance with the recommendations
in the Guide for the Care and Use of Laboratory Ani-
mals of the National Institutes of Health. All experi-
ments on animals are conducted in accordance with the
3R rule and at the same time with taking into consider-
ation the right number of the animals in groups making
it possible to run the statistical analysis.
The isolation of hADSCs
The subcutaneous adipose tissue specimens (n = 12)
were collected during planned surgery in Maria Skło-
dowska-Curie Memorial Cancer Center and Institute of
Oncology, Gliwice Branch (Poland). Researches using
human adipose tissue has been accepted by the Commit-
tee on the Bioethics Maria Sklodowska-Curie Institute -
Oncology Center, Gliwice Branch (Permit Number: KB/
430-35/14).
The adipose tissue was rinsed with PBS− (Gibco BRL,
Paisley, UK) and supplemented with 1% of FBS (Gibco).
The tissue was incubated with NB4 collagenase solution
(0.4 U/mL, Serva Electrophoresis, Heidelberg, Germany)
in Ham’s F-12 medium (Life Technologies, Carlsbad,
CA, USA) supplemented with 10% of FBS and Ca2+ (2.5
mM, Sigma Aldrich, St Louis, MO,USA) for 70 min. in
37 °C with shaking (250 rpm). After the digestion, the
cell suspension was centrifuged (1500 rpm, 10 min) and
the cells were suspended in red blood cell lysis buffer
(Miltenyi Biotec, Bergisch Gladbaels, Germany) for 10
min at RT. After the centrifugation, the cells were sus-
pended in PBS− and filtered through 70-μm cell strainer.
The suspension of single cells was placed on plastic cul-
ture dishes (6 × 106 cells/10 cm plate) in DMEM
medium with high glucose concentration (4.5 g/L) (Life
Technologies) supplemented with 20% FBS and antibi-
otics (penicillin and streptomycin, Sigma Aldrich) (acc.
to [10]). Cells were incubated at 37 °C with 5% of CO2.
After 72 h, the cells were washed twice with PBS− to re-
move nonadherent cells and a fresh culture medium was
added to the plates. The medium was changed every 2–
3 days. The experiments were conducted on cells after
the second passage.
Cell culture
Mouse adipose-derived (mADSCs) and mouse bone
marrow-derived (mBM-MSCs) mesenchymal stromal
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cells were used. Murine (L929) and human (NHDF,
GM07492) fibroblasts were also used. The mADSCs
were isolated from the inguinal adipose tissue of 8–
10-week-old C57BL/6NCrl female mice. The tissue was
collected and incubated with NB4 collagenase solution
(0.4 U/mL, Serva Electrophoresis) in Ham’s F-12
medium (Life Technologies) supplemented with 10%
FBS and Ca2+ (2.5 mM, Sigma Aldrich) for 70 min at 37 °
C with shaking (250 rpm). After the filtration through a
70-μm cell strainer and centrifugation, the cells were
suspended in a medium and placed on culture dishes.
mBM-MSCs were isolated from 6–8-week-old C57BL/
6NCrl female mice. Femurs and tibias from mice were
dissected and rinsed with IMDM medium (Gibco). The
bone fragments were incubated with NB4 collagenase so-
lution (3mg/mL) in IMDM medium with 10% FBS and
Ca2+ (2.5mM) (250 rpm with shaking, 37 °C, 3 h). After
the filtration through a 70-μm cell strainer and centrifuga-
tion, the cells were suspended in a medium and placed on
culture dishes. L929 cells (NCTC clone 929, ATCC, Ma-
nassas, USA) were cultured in RPMI 1640 medium (Life
Technologies) supplemented with 10% of heat-inactivated
FBS and antibiotics (penicillin and streptomycin, Sigma
Aldrich). NHDF (Lonza, Basel, Switzerland) and
GM07492 (Coriell Cell Repositories, NJ, USA) cells were
cultured in DMEM medium with high glucose and sup-
plemented with 10% FBS and antibiotics (penicillin and
streptomycin). mADSCs and mBM-MSC were cultured in
IMDM medium supplemented with 10% FBS and antibi-
otics (penicillin and streptomycin). Cells were incubated
at 37 °C with 5% of CO2.
Analysis of the phenotype and differentiation capacity of
hADSCs
The single-cell suspension was incubated for 30 min at
4 °C with antibodies directed against the following hu-
man antigens: CD105-APC, CD29-FITC, CD73-PE,
CD90-PECy7, CD44-FITC, CD34-PE-Cy7, CD31-FITC,
KDR-PE, CD146-PE, CD45-PE, Lin-FITC, HLA-DR-
PECy7 (BD Pharmingen, San Diego, CA, USA), and suit-
able isotype control antibodies. 7-AAD (7-amino-actino-
mycin D; eBioscences) was used to stain nonviable cells
just before running the flow analysis. The samples were
analyzed using a flow cytometer (BD FACSCanto™, BD
Biosciences). To examine the adipogenic and osteogenic
differentiation capacity of the isolated cells, we used The
Human Mesenchymal Stem Cell Functional Identifica-
tion Kit (RayBiotech, Norcross, GA, USA) in accordance
with the manufacturer’s instructions. The hADSCs were
cultured for 21 days in the adipogenic and osteogenic
differentiation medium. The ability of the hADSCs to
differentiate into osteoblasts was assessed by histochem-
ical staining using Alizarin Red (Aldrich). The cells were
visualized using an Eclipse 80i microscope (Nikon
Instruments Inc., Melville, NY, USA). The ability of
hADSCs to differentiate into adipocytes was assessed by
immunofluorescence staining using an antibody directed
against the FABP4 (Fatty Acid Binding Protein, Abcam)
and a secondary antibody linked to an FITC fluoro-
chrome (Vector Laboratories). Fluorescence imaging of
the stained cells was performed using a LSM710 con-
focal microscope (Carl Zeiss Microscopy GmbH).
Determination of IL-6 secreted in vitro by hADSCs
hADSCs were cultured for 24 h in standard conditions.
Then, the cells were fixed with 4% paraformaldehyde
(Sigma Aldrich) and stained with Phalloidin conjugated
with Alexa Fluor 594 (Abcam, Cambridge, UK). The sec-
tions were incubated with an antibody directed against
human interleukin 6 (Abcam). Subsequently, the sec-
tions were incubated with a secondary antibody conju-
gated with FITC (Vector Laboratories, Burlingame, CA,
USA). Sections were mounted in VECTASHIELD
Mounting Medium with DAPI (Vector Laboratories).
Imaging of the fluorescence of the stained sections was
performed with the confocal microscope LSM710 (Carl
Zeiss Microscopy).
Determination of IL-6 secreted by hADSCs and mADSCs
using ELISA test
hADSCs and mADSCs were cultured in standard condi-
tions in serum-containing complete medium. On the
next day of the culture, the medium was replaced with
DMEM without the serum. After 4 h, the medium was
replaced with a fresh one. After 2, 4, 8, 16, 24, and 48 h,
the medium was collected and stored at − 80 °C until
needed. ELISA kits (eBioscience) were used according to
the manufacturer’s instructions to determine the levels
of the secreted IL-6.
The total protein amount in the conditioned medium
was determined by the Bradford method.
The murine model of hind limb ischemia
The unilateral femoral artery ligation was performed on
10–12-week-old male C57BL/6NCrl (immunocompe-
tent) and NOD SCID (immunodeficient) mice. The mice
were originally purchased from Charles River Laborator-
ies (Wilmington, MA, USA). Animals were anesthetized
with 2% isoflurane (MiniVent Model 845, Harvard Ap-
paratus, USA). The skin from the inner side of the left
hind limb was incised over a length of about 1 cm, and
the superficial femoral artery was exposed. The artery
was ligated at two points using surgical sutures. First
ligation was performed about 0 .5cm from the hip joint
and the other about 1 cm further down from the first
ligation. The skin incisions were closed. The body
temperature was maintained with heating pads until the
animals recovered from surgery. An hour after the
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ligation, the administrations of hADSCs, mADSCs,
mBM-MSCs, L929, GM07492, and NHDF cells (1 × 106
cells suspended in 100 μL of PBS-) into the gastrocne-
mius muscles were performed. We also administrated
150 ng of recombinant murine or human IL-6 (Abcam)
in a total volume of 100 μL in PBS into the gastrocne-
mius muscle once an hour after the ligation. The control
mice were injected with 100 μL of PBS−.
Angiography
The magnetic resonance angiography experiments were
performed on a 9.4 T vertical 89-mm-bore system (Bruker
BioSpin, Rheinstetten, Germany) equipped with a Bruker
Micro 2.5 gradient system and a transmit/receive birdcage
radio frequency coil with an inner diameter of 30mm.
During data collection, animals were anesthetized with 2–
3% solution of sevoflurane. Body temperature and respir-
ation rate were monitored using ECG/respiratory unit (SA
Instruments, Inc., Stony Brook, NY, USA). Images of vas-
cular system were acquired using a multi-slice 2D TOF
(time of flight) flow compensated sequence using the fol-
lowing parameters: TE = 3.1ms, TR = 12ms, flip angle =
80°, field of view 2 × 3cm2, matrix size 200 × 300, slice
thickness 0.3 mm, inter-slice distance 0.2mm, and num-
ber of signal averages 3.
In vivo assessment of limb function
A semiquantitative assessment of the impaired use of
the ischemic limb was performed using the following
criterion: 3—dragging of foot, 2—no dragging but no
plantar flexion, 1—plantar flexion, and 0—flexing the
toes to resist the gentle traction on the tail.
Flow cytometric analysis of macrophages in the ischemic
muscle
Flow cytometry was used to determine the subsets of
macrophages in the ischemic muscles. Seven days after
the artery ligation and hADSCs, mADSCs, or PBS− ad-
ministrations, the muscles were collected, minced, and
digested with collagenase II solution for 1 h at 37 °C
(500 U/mL; Gibco). The red blood cells were lysed using
0.15M ammonium chloride solution (Sigma Aldrich).
The cell suspensions were filtered through 70-μm cell
strainer. The dead cells were removed by centrifugation
using Histopaque-1077 gradient (Sigma Aldrich). Cells
were incubated with rat anti-mouse CD16/CD32 block-
ing antibody (eBioscience) and then incubated with
anti-CD45 (BioLegend), anti-F4/80 (eBioscience),
anti-CD206 (Bio-Rad), and anti-CD86 (Biologend) anti-
bodies for 30 min. All FACS-analyzed populations were
gated in a 7-AAD (eBioscience) window to enrich for
live cells. To analyze the macrophage phenotype,
7-AAD-viable muscle derived cells and CD45 (to identify
lymphoid cells) were gated and then F4/80 (to identify
macrophages) and CD206 (to identify CD45+/ F4/80+/
CD206+; M2 macrophages) and CD86 (to identify
CD45+/ F4/80+/ CD86+, M1 macrophages). Gates divid-
ing negative from positive cells were based on the iso-
type antibody control probes in the flow cytometric
analysis (BD FACSCanto, BD) [23].
Determination of human and murine interleukin-6 in
serum and tissue after ADSCs injection
Seven days after the artery ligation and hADSCs,
mADSCs, or PBS− administration, mice were sacrificed
by cervical dislocation. The blood was collected into BD
Vacutainers and left for 30 min for clotting and then
centrifuged. The serums were collected and stored at −
80 °C until needed. The gastrocnemius muscles were
collected and stored at − 80 °C until needed. The frozen
tissues were homogenized and incubated in cell lysis
buffer with proteases cocktail (Thermo Scientific). The
homogenates were centrifuged at 4000 rpm for 10 min at
4 °C. The supernatants from homogenized muscles were
collected. The concentration of human and murine IL-6
in collected supernatants and serum was determined by
ELISA (eBioscience) in accordance with the manufac-
turer’s instruction. The total protein amount in the ho-
mogenates was determined by the Bradford method.
The histochemical staining
One, 3, 7, 14, and 21 days after the surgery, mice were
sacrificed by cervical dislocation and the gastrocnemius
muscles were collected for immunohistochemical ana-
lysis. The collected muscles were frozen in liquid nitro-
gen and stored at − 80 °C until needed. Subsequently,
frozen tissues were sectioned into 5-μm slices.
The frozen sections were examined histochemically
(hematoxylin/eosin staining, Sigma Aldrich), and the
analysis of the specimens was conducted using the
Nikon Eclipse 80i microscope (Nikon Instruments Inc.,
Melville, NY, USA).
The identification of hADSCs in gastrocnemius muscles
The hADSCs were identified in the gastrocnemius mus-
cles using murine monoclonal primary antibody directed
against the human LAMIN A + C—Nuclear Envelope
Marker (Abcam, 1:100). Sections were stained in accord-
ance with the manufacturer’s instruction for the Vector
M.O.M. Fluorescein Kit (Vector Laboratories). To confirm
IL-6 secretion in tested muscles, the sections were add-
itionally incubated with an antibody against human inter-
leukin 6 (Abcam). To confirm that macrophages were
located at the site of hADSCs’ administration, the sections
were additionally incubated with anti-CD206 antibody
(Abcam). Subsequently, the sections were incubated with
a Texas Red conjugated secondary antibody (Vector La-
boratories). Sections were mounted in VECTASHIELD
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Mounting Medium with DAPI. Imaging of the fluores-
cence of the stained sections was performed with the con-
focal microscope LSM710 (Carl Zeiss Microscopy).
The immunohistochemical assessment of blood vessels
and macrophages in gastrocnemius muscles
To determine the newly formed vessels in gastrocnemius
muscles after the hADSCs administration, the frozen
sections were stained immunohistochemically. The fro-
zen sections were incubated with antibodies directed
against rat CD31 and rabbit CD146, α-SMA (Abcam).
Additionally anti-F4/80 and anti-CD206 antibodies
(Abcam) were used to identify M2 macrophages. Subse-
quently, sections were incubated with a secondary anti-
bodies conjugated with Texas Red, FITC, or Alexa Fluor
(Abcam). Sections were mounted in VECTASHIELD
Mounting Medium with DAPI (Vector Laboratories).
Imaging of the fluorescence of the stained sections was
performed with the confocal microscope LSM710.
The macrophages depletion
In order to deplete the macrophages, 200 μL of clodro-
nate liposomes solution or PBS− liposomes in an amount
of 1 mg/mL (Clodronate Liposomes Organization, Vrije
Universiteit, Netherlands) was injected i.v. using a
26-gauge needle. The liposomes were injected twice—48
h and 1 h—before the hADSCs or PBS− administration
to ensure depletion of resident macrophages and every
2/3 days after cell injection to deplete infiltrating macro-
phages. hADSCs or PBS− were injected as previously de-
scribed. On the 7th day of the experiment, the muscles
were collected, frozen in liquid nitrogen, and stained to
show mature macrophages (F4/80) and the M2 macro-
phages (CD206) to confirm the macrophages depletion.
The effect of macrophages depletion on the formation of
the new blood vessels was determined using anti-CD31
antibody staining as described previously.
Blocking of human IL-6 in vivo
Blocking of human IL-6 secreted by hADSCs in vivo was
achieved using an antibody against human IL-6—siltuxi-
mab (10mg/kg) (Janssen Cilag, Turnhoutseweg, Belgium).
Siltuximab was injected i.v. 2 days and 1 h prior and every
2/3 days after the hADSCs or PBS− injection. hADSCs or
PBS− were administered as previously described. On the
7th day of the experiment, the muscles were collected, fro-
zen in liquid nitrogen, and stained with anti-CD31 anti-
body as described previously. To confirm the effect of
depletion of IL-6, secreted by hADSCs, on the macro-
phage infiltration, the muscles were stained with F4/80
and CD206 antibodies as previously described.
Statistics
The results were analyzed with the appropriate tests
using the Statistica software (Dell Inc. (2016). Dell Sta-
tistica (data analysis software system), version 13. soft
ware.dell.com). P values < 0.05 were considered statisti-
cally significant.
Results
The phenotype of hADSCs stabilized during cell culture
The human hADSCs were isolated from subcutaneous
adipose tissue from the abdominal region. Flow cytome-
try analysis showed that hADSCs expressed CD105,
CD90, CD73, CD44, and CD29 surface markers and
were negative for CD45, CD34, HLA-DR, KDR, and
CD31 antigens (Fig. 1a). The phenotype of hADSCs was
stabilized after the second passage during cell culture.
Isolated cells in vitro differentiated towards adipocytes
(Fig. 1b) and osteoblasts (Fig. 1c).
The retention time of hADSCs cells in the injured limb is
14 days
On 3, 7, and 14 days after the hADSCs injection, we col-
lected the gastrocnemius muscles and used immunohis-
tochemical staining to identify the human nuclear
protein—Lamin A/C in the murine muscles (Fig. 1e). It
was observed that on day 14 after the surgery hADSCs
were still present in the gastrocnemius muscles of the
injured limbs (data not shown).
The administration of the hADSCs cells to the injured
limb accelerated its functional recovery
We started the evaluation of the limb motor functions
on the second day after the artery ligation (Fig. 2a). De-
pending on the degree of use of the damaged limb by
the mouse during movement, the score was 3, 2, 1, and
0 points [11]. Based on that assessment, it was found
that mice receiving hADSCs, starting on the third day
after the procedure, began to support the gait on the in-
jured limb, whereas in the control mice the limb was
constricted and impaired. On day 14, we observed only
slight differences in the movement of the mice of both
groups and the motor functions of the damaged limbs
were comparable to the healthy ones.
The MR angiography of the vascular system in the
damaged limb after the hADSCs implantation
In order to investigate changes in the vessels in the is-
chemic limb, we utilized an angiographic examination.
The study was carried out on days 0, 3, 7, and 14. The
test on day 0 (day of arterial ligation) confirmed the effi-
ciency of ligation of the femoral artery (Fig. 2b, f ). Dur-
ing the study, we observed no significant differences in
the angiograms of the injured limb in both groups of
mice. On day 14, the artery system after ligation was
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similar to the artery system in the healthy limb, in the
group of mice that received hADSCs as well as in PBS−
(Fig. 2e, i).
The administration of hADSCs accelerates the repair of
the damaged muscle
To show the changes in muscle tissue after the hADSCs
administration, we collected the tissue for histochemical
staining procedure on days 3, 7, 14, and 21. In the con-
trol muscles, necrotic muscle fibers were observed up to
day 14 (Fig. 2j, k, l). One week after the administration
of hADSCs, we observed extensive muscle regeneration
(regenerative small, basophilic muscle fibers with one or
more centrally located nuclei) (Fig. 2o). On day 21, the
muscles treated with hADSCs and the control muscles
resembled healthy tissues—the fibers were typically pol-
ygonal and the sarcolemmal nuclei were located periph-
erally (Fig. 2m, r).
The administration of hADSCs increases macrophages
infiltration in the mouse model of hindlimb ischemia as
compared to mMSC
In the muscles, 3 days after the administration of
hADSCs, we observed a significant increase in the area
Fig. 1 The hADSCs characteristics in vitro and their retention time after the administration to the murine muscle tissue. a Phenotype of hADSC
(passage #2; n = 12 Flow cytometry). The phenotype fulfills all the accepted criteria for MSCs identification; b adipogenic differentiation—formation of
lipid vesicles stained with FABP4 antibody (green, passage #2, n = 5); c osteogenic differentiation—calcium deposits stained with Alizarin Red (red,
passage #2, n = 7, magn × 20); d immunofluorescence phalloidin staining of actin filaments (red) and Lamin A/C (green) in hADSCs in vitro. e The
representative image of double immunofluorescent staining of human specific Lamin A/C (green) and macrophages (CD206, red) on day 7. Image
shows that injected hADSC localize in clusters, presumably at the injection site. f Image shows control immunofluorescence staining with secondary
Biotinylated Anti-Mouse and Fluorescein Avidin antibodies alone. Nuclei were stained with DAPI (blue), scale bars = 50 μm
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occupied by cells expressing F4/80 (immunofluores-
cence; 15.23% of the area) as compared to the control
(PBS−) (4.29% of the area) and both murine MSC
groups: mADSCs (1.97% of the area) and mMB-MSCs
(0.52% of the area). On day 7, the areas of F4/80 positive
cells in hADSCs group were increased to 18.62% of the
total area, mADSCs group—4,88%, and mBM-MSCs
group—3.23%, while in PBS group was 1.19% of the total
area. Almost all macrophages (F4/80+ cells) also pos-
sessed the CD206 antigen (M2 macrophages) (Fig. 3).
Additionally, we conducted a cytometric analysis of the
macrophages in the muscles on the seventh day after the
artery ligation. In all three groups (hADSCs, mADSCs
and PBS−), we identified a larger number of M2 macro-
phages (defined as 7-AAD−/CD45+/F4/80+/CD206+)
than M1 macrophages (defined as 7-AAD−/CD45+/F4/
80+/CD86+). In the muscles of the mice which were
injected with both hADSC and mADSC, we observed an
increased number of M2 macrophages in comparison to
the control group (hADSC—over 60-fold higher;
mADSC—almost 10-fold higher) (Fig. 3j).
The administration of hADSCs increases angiogenesis in
the murine model of hindlimb ischemia
The administration of hADSCs into ischemic muscle sig-
nificantly increased the number of newly formed
Fig. 2 MR imaging of vascular system and muscle regeneration in mouse gastrocnemius muscle after the hindlimb ischemia. The mice given
hADSC demonstrated improved functional outcomes as compared to the control mice (PBS−) (n = 10)*p < 0.05, **p < 0.01 by the U Mann-Whitney
test (a). Effectiveness of femoral artery ligation and consecutive restoration of the blood flow in the ischemic hindlimbs were visually evaluated
using magnetic resonance angiography. Representative magnetic resonance angiography images (maximum intensity projections) of mouse
hindlimbs were acquired immediately after the femoral artery ligation (b—control mouse, f—hADSC treated mouse), on day 3 (c—control
mouse, g—hADSC treated mouse), on day 7 (d—control mouse, h—hADSC-treated mouse) and on day 14 (e—control mouse, i—hADSC-treated
mouse). The representative images of the transverse sections of the gastrocnemius muscle tissues by H&E staining after PBS− (j, k, l, m) and
hADSC (n, o, p, r) injection at 3, 7, 14, and 21 days after surgery. Necrotic muscle fibers (black arrows) with pale cytoplasm were observed at 3 (j),
7 (k), and 14 (l) days after the PBS− administration. Regenerative small, basophilic muscle fibers with one or more centrally located nuclei (white
arrows) were observed in all hADSC groups. Scale bar: 100 μm (× 20 magnification)
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capillaries compared to the control group (PBS−)
(Fig. 4a). By the seventh day, the number of new microves-
sels (CD31+) was twice as high (848/mm2) as after the ad-
ministration of PBS− (424/mm2). Until the 14th day after
the surgery, the number of microvessels after hADSCs ad-
ministration increased significantly (1343/mm2) compared
to day 7 and was almost twice as high as in the control
group (726/mm2). After 3 weeks, the number of
microvessels in both groups decreased. However, a signifi-
cant difference was still observed. In the group in which
hADSCs were administered, the number of microvessels
was higher (726/mm2) than in the control group (475/
mm2). The newly formed microvessels present in the mus-
cles were composed of endothelial cells and pericytes sur-
rounding them (CD146+) (Fig. 4c). In turn, the amount of
large blood vessels (α-SMA+) was the highest on day 7 after
Fig. 3 hADSCs injection in the ischemic muscles increased the infiltration of the proangiogenic M2 macrophages. Immunofluorescence analyzes
in collected muscles 3 (a, b, c, d) and 7 (e, f, g, h) days after the ligation of the artery and the administration of hADSC (d, h), mADSC (c, g),
mBM-MSC (b, f), and control (PBS−) (a, e). The representative images of M2 macrophages (F4/80+ (red) / CD206+ (green)). The images show that
after the hADSC injection into ischemic muscle the infiltration of the proangiogenic macrophages M2 was observed on the 3rd day after the
surgery and it increased at day 7. After the administration of mBM-MSC and PBS−, the significant M2 macrophage infiltration was not observed.
However, after the administration of mADSC an increase in macrophage infiltration was observed on day 7. The graph of the total area of F4/80
macrophages in collected muscles on the 3rd and 7th day after the surgery (I). The total area occupied by F4/80 macrophages was calculated
using ImageJ software in 10 fields of view at a magnification of 40 × (n = 5; 5 muscles per group were analyzed; 10 pictures of each muscle were
taken). Using the flow cytometry 7 days after the artery ligation and administration of the hADSCs, mADSCs, and PBS− in collected muscles the
number of M1 (defined as 7-AAD−/CD45+/F4/80+/ CD86+) and M2 (defined as 7-AAD−/CD45+/F4/80+/CD206+) macrophages was evaluated (j). In
all researched groups we observed a greater number of M2 macrophages in comparison to M1 macrophages. The largest number of M2
macrophages was found in muscles after the administration of hADSCs: six times more than mADSCs group and sixty times more than PBS−
group. The ratio of M2 to M1 macrophages was 686 in hADSCs group, 824 in mADSCs group and 364 in PBS− group (n = 5). **p < 0.001
evaluated with Kruskal-Wallis one-way analysis of variance and multiple comparison of mean ranks for all groups. ***p < 0.0005 by the ANOVA
followed by the Tukey’s post hoc test. Nuclei stained with DAPI (blue), scale bars = 50 μm
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the administration of the hADSCs (1.13% of the area), com-
pared to the control where we observed only few large
blood vessels (0.19% of the area) (Fig. 4d).
We also examined the proangiogenic properties of
murine MSC and fibroblasts, both murine and human
(Fig. 4b). None of the three fibroblast cell lines (L929,
GM07492, NHDF) increased the number of blood ves-
sels in the gastrocnemius muscle on the 14th day after
the surgery. In the group, where the murine MSC iso-
lated from the bone marrow were injected into the
Fig. 4 The administration of hADSCs increases the angiogenesis in mouse model of the hindlimb ischemia. Capillaries (CD31 positives cells)
count in collected muscles 7, 14, and 21 days after the artery ligation and the administration of hADSC or PBS− (a). The Number of capillaries in
collected muscles 14 days after the artery ligation and the administration of hADSC, mADSC, mBM-MSC, L929, GM07492, NHDF, and PBS− (b). The
number of the vessels (CD31+) in each group was determined in 10 fields of view at a magnification of 40x and calculated per 1mm2 of tissue (n= 5; 5
muscles per group were analyzed; 5 (for total area of F4/80) or 10 (for number of capillaries) pictures of each muscle were taken). **p< 0.05, ***p< 0.001
evaluated with Kruskal-Wallis one-way analysis of variance and multiple comparison of mean ranks for all groups (hADSCs statistically significant with each
group except the mADSC group, p = 0.235). Nuclei stained with DAPI (blue), scale bars = 50 μm. The immunostaining of pericytes CD146 (red)/endothelial
cells (green) with nuclei staining (blue) (c). The immunostaining of αSMA (green)/endothelial cells (red) with nuclei staining (blue) (d)
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hindlimb, we observed comparable number of blood
vessels (556/mm2) to the control group (636/mm2). The
administration of both murine and human MSCs iso-
lated from adipose tissue significantly increased the
number of blood vessels on the 14th day compared to
the control group (PBS−). After the administration of
hADSCs in the gastrocnemius muscle, 106% more ves-
sels (1406/mm2) were observed, and after administration
of mADSCs, 55% more blood vessels (1060/mm2) were
observed as compared to the control group.
Injected hADSCs secrete interleukin 6 and cause
infiltration of macrophages in murine ischemic
gastrocnemius muscle
Before administering hADSCs to mice, we checked
whether these cells secrete interleukin 6. The levels of
IL-6 secreted in vitro by both hADSCs and mADSCs
increased in a time-dependent manner (Fig. 5a, b). The
amount of secreted IL-6 by murine ADSCs was signifi-
cantly lower compared to human ADSCs. Immunohisto-
chemical staining showed that interleukin 6 was located
in hADSCs in vitro (Fig. 5c). Interleukin 6 was located
around hADSCs after injection into the muscle (Fig. 5d,
e). We investigated the amount of the secreted IL-6 in
vivo after the ADSCs administration. The amount of IL-6
secreted in the gastrocnemius muscle after administering
the murine ADSCs was sevenfold higher compared to
hADSC (Fig. 5f, g). We observed slightly more of IL-6 in
the muscles than in the serum after the administration of
hADSCs. However, after administering the murine
ADSCs, we did not found IL-6 in the serum (Fig. 5g).
Furthermore, at the site of administration of hADSCs, we
observed the M2 macrophages (CD206+) infiltration
(Fig. 1e–g).
Fig. 5 hADSCs secrete interleukin 6. The levels of IL-6 secreted by hADSCs (a) and mADSCs (b) in vitro were determined by ELISA. The amounts
of secreted IL-6 were calculated for 1 mg of total protein content. The immunofluorescence staining of interleukin 6 (green) and hADSCs (red) (c).
The representative images of the double immunofluorescence staining of human specific Lamin A/C (green) and interleukin 6 (red) (d, e). The
images show that the injected hADSC localized in clusters, presumably at the injection site, and interleukin 6 was located around hADSCs on the
third (d) and the seventh (e) day after the cell injection in the ischemic limb muscles. The amounts of the secreted IL-6 by human ADSCs (f) and
murine ADSCs (g) in the murine muscle and serum was determined by ELISA test on the 3rd after artery ligation (n = 5). **p < 0.01 evaluated
with U Mann-Whitney test. Nuclei were stained with DAPI (blue), scale bars = 50 μm
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The depletion of macrophages suppressed the
therapeutic effect induced by hADSCs
We investigated the role of macrophages in the regener-
ation processes in damaged muscles after the hADSCs
administration. For this purpose, we used liposomes with
hADSCs with clodronate to deplete macrophages in
vivo. While the hADSCs injection increased the number
of F4/80+/CD206+ cells (macrophages M2) in the gastro-
cnemius muscle (Fig. 6b), injection of clodronate lipo-
some reduced the infiltration of macrophages (Fig. 6c).
The number of F4/80+ cells was significantly higher
(38.69% of the area) in hADSCs group as compared to
the hADSCs with clodronate liposome group (0.75% of
the area) and PBS− with clodronate liposome group
(0.03% of the area) (Fig. 6g). Additionally, we observed
no increase in the number of newly formed blood vessels
(CD31+) in hADSCs with clodronate liposomes group
(379/mm2) compared to hADSCs group (721/mm2)
(Fig. 6h).
The administration of hADSCs in a model of hindlimb
ischemia in NOD SCID mice increases angiogenesis but
does not regenerate the muscle
After the administration of hADSCs into ischemic
muscle of NOD SCID mice, we did not observe the
muscle regeneration on days 7 (Fig. 7a, c) and 14 (Fig. 7b,
d). We observed the necrotic muscle fibers in the con-
trol muscles (Fig. 7a, c). Moreover, macrophages infiltra-
tion in both hADSCs and PBS− groups was not observed
(Fig. 7e, f, g). However, we observed an increase in the
number of newly formed blood vessels (CD31+) after the
hADSCs administration on days 7 and 14 (compared to
the control group) (Fig. 7h).
Blocking IL-6 secretion by hADSCs in vivo suppresses the
therapeutic effect induced by these cells
Human interleukin 6 secreted in vivo was blocked using
siltuximab. After in vivo blocking of the IL-6, we did not
observe the macrophages infiltration 7 days after the ad-
ministration of the hADSCs (Fig. 8c). We observed a sig-
nificant decrease in the area occupied by cells expressing
F4/80 in gastrocnemius muscles after the injection of
hADSCs and after the administration of siltuximab
(0.39% of the area) as compared to the group receiving
the cells alone (32.3% of the area) (Fig. 8g). Likewise, in
groups with siltuximab and hADSCs, we did not observe
an increase in the number of newly formed blood vessels
(CD31+) (432/mm2) compared to group receiving
hADSCs alone (736/mm2) (Fig. 8h).
The administration of interleukin 6 alone has no
therapeutic effect in mouse model of hindlimb ischemia
We checked whether the administration of interleukin 6
alone would induce a similar therapeutic effect as the
administration of IL-6 secreting hADSCs and mADSCs
cells. For this purpose, we administered recombinant hu-
man or murine IL-6 proteins to mice. We observed
muscle regeneration (regenerative small muscle fibers
with one or more centrally located nuclei) 7 days after
the hADSCs administration (Fig. 9e). No muscle regen-
eration was observed after PBS− (Fig. 9a), murine inter-
leukin 6 (mIL-6) (Fig. 9b), human interleukin 6 (hIL-6)
(Fig. 9c), and mADSCs (Fig. 9d) administration. Add-
itionally, after the mIL-6 injection, we observed exten-
sive muscle degeneration (many necrotic muscle fibers
with irregular internal architecture). The administration
of murine interleukin 6 into muscle did not increase the
number of new blood vessels (543/mm2), but the admin-
istration of human interleukin 6 (hIL-6) increased sig-
nificantly the number of new blood vessels by 29% (682/
mm2) as compared to the control group (PBS) on the
seventh day after the surgery. However, the number of
new blood vessels after the hADSCs administration was
24% higher compared to human IL6 and after mADSCs
administration, it was twice as high compared to murine
IL-6 (Fig. 9l). After the administration of mIL-6 and
hIL-6, twice as many macrophages, respectively, 0.695%
of the area and 0,615% of the area as compared to con-
trol group (PBS−) (0.32% of the area) were observed.
However, this amount of macrophages was significantly
lower compared to hADSC group (32.3% of the area)
and mADSCs group (4.88% of the area) (Fig. 9k).
Discussion
The aim of our work was to explain the mechanism of
the repair of the damaged muscle in the hind limb
ischemia model with the participation of human
adipose-derived mesenchymal stromal cells (hADSCs).
The isolation of mesenchymal cells from adipose tissue
has many advantages. Adipose tissue collection, most often
during liposuction, is safe and easy, and the isolation of cells
from collected samples is highly efficient [5]. It is estimated
that it is about five times more efficient than, for example,
isolation from the bone marrow [12]. Due to the properties
of ADSCs, there have been many researches looking for the
possibility of using it in different types of therapies con-
nected to the repair of the damaged tissues [13–16].
hADSCs, depending on the environmental context,
show anti- or proinflammatory properties [17–21]. They
interact with macrophages [21], T and B lymphocytes
[22], and NK cells [23]. Therefore, in our studies, we de-
cided to use two mice strains: immunocompetent
C57BL/6NCrl strain and NOD SCID strain with defect-
ive immune system.
In the first stage of the study, we examined the reten-
tion time of hADSCs transferred into the muscle of
C57BL/6NCrl mice. Fourteen days after administration,
the cells were still present in the muscle (data not
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Fig. 6 Depletion of macrophages using liposomes with clodronate abolishes the therapeutic effect induced by hADSCs. The immunofluorescence
analyzes of blood vessels and macrophages 7 days after the artery ligation and hADSCs and clodronate liposomes administration (hADSCs
+clodronate liposomes) and control group (hADSCs+PBS liposomes). The representative images of M2 macrophages (F4/80+ (red)/CD206+
(green)) (a, b, c) and blood vessels CD31+ (green) (d, e, f). The graph of the total area of F4/80 macrophages (g) and capillaries (CD31) (h) in
collected muscles. The images and the graph show that liposomes containing clodronate effectively deplete F4/80+ and F4/80+CD206+ cells in
mouse gastrocnemius muscles in vivo (c), (g). After the depletion of macrophages an increase in the number of blood vessels was not observed
in muscles where hADSC were administrated (f), (h) (n = 10; 10 muscles per group were analyzed; 5 (for the total area of F4/80) or 10 (for the
number of capillaries) pictures of each muscle were taken). *p < 0.05, ***p < 0.001 evaluated with Kruskal-Wallis one-way analysis of variance and
multiple comparison of mean ranks for all groups. Nuclei stained with DAPI (blue), scale bars = 50 μm
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Fig. 7 (See legend on next page.)
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shown). In the study by Dao et al. [24], the retention
time of hADSCs in murine ischemic limb was shorter
and lasted 8 days. The differences in the assessment of
the retention time in both studies may be due to differ-
ent methods of cells identification in the tissue.
After the procedures of artery ligation and administra-
tion of hADSCs, the condition of the mice, especially
the mobility of the damaged limb, were evaluated daily.
We observed that on the third day after the surgery the
gait of mice that received hADSCs was supported by the
damaged limb and in control mice the limb was still im-
paired. On day 14 after surgery we only observed slight
differences in the movement ability of mice of both
groups (Fig. 2a).
A similar assessment was presented in the article [11]
in which therapy with the use of mouse mesenchymal
cells isolated from the bone marrow was conducted. On
day 14, we observed the normal morphology of muscle
fibers (Fig. 2m, r). It confirms that the process of the re-
pair of the damaged limb after artery ligation takes about
2 weeks and administration of hADSCs accelerates this
process.
We observed a higher number of newly formed vessels
in the injured muscle to which the hADSCs were admin-
istered than in the control mice. The number of newly
formed capillaries was changing during the study. The
highest number of blood vessels was noted on day 14
after the hADSCs administration and then the number
decreased on day 21 to a level slightly lower than on day
7. We observed a similar process in the group of control
mice that received PBS. The number of capillaries was
the highest on day 14 to then decrease on day 21 to the
level from day 7. On day 21, the number of capillaries in
the hADSCs group was higher than that in the PBS−
group (Fig. 4a). Similarly, to others [25], we observed
that this reduction in the number of capillaries is the re-
sult of the formation of large, functional blood vessels
and the stabilization of the microenvironment in the
limb.
We observed infiltration of macrophages with the M2
phenotype characterized by the proangiogenic and im-
munosuppressive properties in the vicinity of the admin-
istered hADSCs.
We should remember that the population of the M2
macrophages is not homogeneous and may be divided
into three main subtypes: M2a, M2b, and M2c [26]. In
our work, we evaluated the number of M1 and M2 mac-
rophages without the exact characteristic of the M2
macrophages population according to their subtypes:
mainly M2a and M2b.
Similar infiltration of macrophages is described in the
publication [27]. In that work, however, the phenotype of
the incoming macrophages had not been determined. M1
macrophages are proinflammatory and cytotoxic while
M2 macrophages are immunosuppressive and proangio-
genic. In our opinion, the authors of the study, like us,
concluded that the infiltration of M2 macrophages is re-
sponsible, among others, for the healing process.
Summarizing, in the muscle after treatment with
hADSCs, a larger infiltration of macrophages with the
M2 phenotype and more capillaries are identified in the
muscles than in the muscles of the control mice.
In our work [28], we observed that IL-6 is a dominant
cytokine secreted by mesenchymal cells isolated from
the myocardium. IL-6 plays a significant role in the re-
pair of the damaged tissues. We decided to determine its
level in the hADSCs culture medium (Fig. 5a). A similar
analysis was also carried out for murine MSCs isolated
from adipose tissue (Fig. 5b) and bone marrow. hADSCs
secreted more IL-6 compared to other cells. In vivo, the
presence of IL-6 was confirmed in the immediate vicin-
ity of hADSCs (Fig. 5d, e), which may prove that this
cytokine is secreted by the mesenchymal cells into the
environment of the damaged muscle.
IL-6 is involved in the polarization of M1 proinflam-
matory macrophages to immunosuppressive and proan-
giogenic M2 macrophages [7, 8]. The human IL-6 is
active in the murine cells. Human and murine interleu-
kin 6 show 65% of homology on the nucleotide level and
41% of homology on the amino acid level. A high level
of homology between mIL-6 and hIL-6 in the region of
the signal peptides was also observed; however, the end
sequences of the polypeptide chain containing the amino
group are different in both species [29]. We found the
infiltration of M2 macrophages with IL-6 receptor ex-
pression in the vicinity of hADSCs (data not shown).
(See figure on previous page.)
Fig. 7 The administration of the hADSCs into the ischemic muscle of immunodeficient NOD SCID mice increases the number of new blood
vessels but does not increase the macrophages infiltration. The representative images of H&E staining of the transverse sections of gastrocnemius
muscle after PBS− (a, b) and hADSCs (c, d) injection on days 7 and 14 post surgery. Necrotic muscle fibers (black arrows) with pale cytoplasm and
regenerative small, basophilic muscle fibers with one or more centrally located nuclei (white arrows) were observed at 7 days after PBS− and
hADSCs administration (a, c). The representative images of M2 macrophages (F4/80+ (red)/CD206+ (green)) after the PBS− (e) and hADSCs (f)
injection 7 days after surgery. Seven days after the hADSCs injection into ischemic muscle of immunodeficient NOD SCID mice, the infiltration of
macrophages was not observed. The graph of the total area of F4/80 macrophages shows that there is no significant difference in the macrophages
presence in the muscles between PBS− and hADSCs groups (g). The number of capillaries (CD31+) in collected muscles 7 and 14 days after hADSCs
and PBS− administration (h). n = 5; 5 muscles per group were analyzed; 5 (for the total area of F4/80) or 10 (for the number of capillaries) pictures of
each muscle were taken. *p < 0.05, ***p < 0.001 evaluated with U Mann-Whitney test. Nuclei stained with DAPI (blue), scale bars = 50 μm
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Fig. 8 IL-6 produced by hADSCs causes an infiltration of the proangiogenic and immunosuppressive M2 macrophages and increases the number
of blood vessels. The immunofluorescence analysis of the muscles collected 7 days after the artery ligation and the administration of hADSCs
with human IL-6 blocking antibody (hADSCs + anti IL-6) and the control group (PBS−). The representative images of M2 macrophages (F4/80+
(red)/CD206+ (green)) (a, b, c) and blood vessels CD31+ (green) (d, e, f). After the administration of IL-6 producing hADSCs the increased
infiltration of M2 macrophages (b) and the increase of blood vessels (e) were observed. After blocking of the IL-6 secreted by hADSCs in vivo no
macrophage infiltration or increase in the number of blood vessels was observed (c, f). The number of capillaries (CD31+) (h) and the total area of
F4/80 macrophages (g) counted in collected muscles 7 days after the administration of hADSC, hADSCs with siltuximab and PBS. n = 5; 5 muscles
per group were analyzed; 5 (for the total area of F4/80) or 10 (for the number of capillaries) pictures of each muscle were taken. ***p < 0.001
evaluated with Kruskal-Wallis one-way analysis of variance and multiple comparison of mean ranks for all groups. Nuclei stained with DAPI (blue),
scale bars = 50 μm
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According to our hypothesis, the M2 macrophages are
activated in the muscle under the influence of IL-6 se-
creted by hADSCs. A similar hypothesis is proposed by
the authors in the work [30] in which they prove that
human mesenchymal cells transform macrophages into
M2 phenotype. The M2 macrophages are involved in the
inhibition of the inflammatory response and initiate re-
pair processes of damaged muscle tissue. To confirm
this assumption, we had planned a few experiments in-
volving the exclusion of one of the elements of the pro-
posed mechanism. In the first experiment, we performed
the depletion of macrophages with the use of liposomes
with clodronate. In the group of mice that were adminis-
tered with hADSCs together with clodronate liposomes,
the number of newly formed vessels was lower than in
mice administered with hADSCs with control liposomes
and higher than the number of vessels in mice treated
only with PBS (Fig. 6h).
We observed a similar effect in NOD SCID mice. This
mouse strain does not have T and B lymphocytes and
macrophages, NK cells. The dendritic cells are impaired.
Similarly, to the clodronate study, we also observed a
greater number of blood vessels than in the PBS control
group (Fig. 7h) but definitely lower than that in C57BL/
6NCrl mice. What is important, we did not observe the
repair of the damaged muscle fibers (Fig. 7b, d). A
greater number of vessels in the group of NOD SCID
mice than in the control group is probably connected to
the secretion of proangiogenic cytokines, such as VEGF,
bFGF, and HGF, by the hADSC cells [30].
We need to remember that IL-6 is a cytokine with a
pleiotropic effect. The literature suggest a possibility of
Fig. 9 The administration of interleukin 6 into ischemic muscle increases the number of new blood vessels but not the macrophages infiltration.
The representative images of H&E staining of the transverse sections of the gastrocnemius muscle after PBS− (a), mouse recombinant interleukin
6 (b), human recombinant interleukin 6 (c), mADSC (d), and hADSC (e) injection on day 7 post surgery. Several necrotic muscle fibers (black
arrows) were observed in muscles after the administration of PBS− (a) human recombinant interleukin 6 (c) and mADSC were observed? (d).
Many necrotic muscle fibers with pale cytoplasm and the irregular internal architecture were observed in muscles after the administration of
mouse recombinant interleukin 6 (b). Regenerative small muscle fibers with one or more centrally located nuclei (white arrows) were observed
only in the muscles after hADSCs administration (d). The representative images of M2 macrophages (F4/80+ (red)/CD206+ (green)) after PBS−,
mIL-6, hIL-6, mADSC, and hADSC injection on the seventh day after the surgery (f, g, h, i, j). The number of capillaries (CD31+) (l) and the total
area of F4/80 macrophages (k) counted in collected muscles 7 days after the administration of hADSC, mouse and human recombinant
interleukin 6, and PBS. n = 5; 5 muscles per group were analyzed; 5 (for the total area of F4/80) or 10 (for the number of capillaries) pictures of
each muscle were taken. *p < 0.05, ***p < 0.001 evaluated with Kruskal-Wallis one-way analysis of variance and multiple comparison of mean ranks
for all groups. Nuclei stained with DAPI (blue), scale bars = 50 μm
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the HGF and VEGF growth factors secretion as a conse-
quence of JAK-STAT3 signal path activation by IL-6 [31].
In the next experiment, we used anti-human IL-6 anti-
body (siltuximab). The inhibition of IL-6 should sup-
press the M2 macrophages. We did not observe an
influx of the M2 macrophages in the mice that received
anti-IL-6 antibody (Fig. 8c, g). The number of newly
formed blood vessels in this group of mice was lower
than in the group of mice that received hADSCs alone,
but comparable to the number of vessels in mice that re-
ceived PBS− (Fig. 8h).
Based on the experience with anti-IL-6, we asked our-
selves a question: Is it sufficient to administer only the
IL-6 protein in order to repair the damaged muscle or is
the presence of the hADSCs necessary? We had planned
an experiment in which we compared the effectiveness
of murine and human IL-6 with the ADSCs administra-
tion. We compared both factors in the same experimen-
tal model. And so, the hADSCs, mADSCs, mIL-6, and
hIL-6 were administered in a single dose directly into
the muscle of the mouse limb an hour after the femoral
artery ligation procedure.
In the mice treated with human or murine IL-6 pro-
teins, the number of macrophages was similar to that of
the mice which were administered with PBS− (Fig. 9k).
However, the number of newly formed vessels in the
group where human IL-6 was administered was higher
than that in the group where murine IL-6 was used
(Fig. 9l). The highest number of incoming macrophages
and newly formed vessels was observed in the group of
mice treated with hADSCs.
There has not been any research so far where IL-6 was
administered directly to the muscle after the femoral ar-
tery ligation, and the effect of this cytokine on the angio-
genesis or the regeneration of the damaged muscle was
appraised. Evaluating the gathered results, we can say
that in this experimental model, with the IL-6 in 150 ng
concentration, we did not observe an increased number
of blood vessels. However, it is possible that the dose
was too small.
According to the literature, the IL-6 is very quickly
eliminated from the blood serum [32], which might have
been the reason IL-6 was completely removed from the
serum after a short time. Probably due to the lack of
IL-6, we did not observe the activation of the M2 mac-
rophages and the number of the blood vessels was not
increased. However, the hADSCs may be treated as a
some sort of “reactor” constantly producing and secret-
ing IL-6 into the blood serum. We can presume that as
long as the hADSCs are present in the muscle of the
mouse, the IL-6 is present in the organism. Even though
its concentration decreases with the depletion of the
hADSCs, it is high enough for the several initial days to
activate the macrophages.
It seems, therefore, that the longer presence of IL-6 in
the blood serum is necessary for the activation of M2
macrophages. Except for the hADSCs, this effect may be
achieved in two ways. The first method is to administer
IL-6 multiple times in short time spans. However, taking
into consideration the rate of the IL-6 degradation from
the serum, it is unlikely. The second method entails an
administration of the IL-6 coding plasmid DNA into the
muscle of the mouse using, e.g., viruses or electropor-
ation. The muscle cells then become, similarly to
hADSC, some sort of “reactors” producing IL-6 and con-
tinuously secrete it into the blood serum. This solution
seems to be more promising, as it is similar to the
hADSC cell therapy. However, we are unable to say if it
is going to be successful.
We need to remember that hADSCs secrete a number
of agents, which activate repair processes in a damaged
tissue. Those agents can be divided into six main cat-
egories: immunomodulatory (IDO, PGE2, HLA-G5,
TGFβ, HGF, NO, LIF, IL-10), proangiogenic (VEGF,
IGF-1, PLGF, MCP-1, bFGF, IL-6, angiopoietin-1),
anti-apoptotic (VEGF, HGF, IGF-1, TGFβ, GM-CSF),
countering the tissue scarring (bFGF, HGF), facilitating
growth and differentiation of the resident stem cells or
progenitor cells (SCF, LIF, IL-6, M-CSF, SDF-1,
angiopoietin-1), and chemokines (CCL2, CCL3, CCL4,
CCL5, CCL7, CCL20, CCL26, CXCL5, CXCL11, CXCL1,
CXCL2, CXCL8, CXCL12) [33]. Those agents are
present where hADSCs are injected, but they are absent
in the microenvironment where we administer only IL-6.
We do not know what effect these factors and the pro-
cesses they activate could have on the mechanism we
describe.
The result of the experiment with the human IL-6 does
not impair its role in our proposed mechanism. It justifies
the usage of the human adipose-derived mesenchymal
stromal cells in the therapy. It seems that the cell to cell
contact and the whole panel of the secreted cytokine, e.g.,
the proangiogenic cytokine (VEGF, HGF), has a signifi-
cance in the repair mechanism of the damaged tissue [34].
We also found that xenografts (human ADSCs) elic-
ited better therapeutic effects than allogenic murine
MSC isolated from bone marrow and adipose tissue.
Therefore, we can pose a question: Was the thera-
peutic effect observed after the administration of the hu-
man MSC into the organism of a mouse a result of the
action of the cells or rather was it caused by the re-
sponse of the immune system to the xenograft? The re-
sults of our research and the reports in the literature
[35–38] indicate that it is rather an effect of the injected
mesenchymal cells, especially that the MSC are charac-
terized by so called immunological privilege [39].
They do not possess on their surface class II MHC an-
tigens and costimulating CD80 and CD86 antigens. They
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possess only small amounts of class I MHC antigens
[40]. It allows them to avoid to be detected and rejected
by recipient’s immune system cells [39].
However, in certain conditions (low level of IFN-γ), MSC
may activate an immunological response [41]. Additionally,
NK cells activated by IL-2 cytokine can lyse the allogenic
MSC. According to Grinnmo et al., the xenografts of MSC
after transplantation into the post myocardial infarction
heart of a rat are rejected by the host’s organism and cause
immune cells infiltration, mainly macrophages, into the site
of the cells transplantation [42].
We cannot exclude a possibility that in certain condi-
tions the immune system of the recipient is activated. It
is connected rather to the status of the microenviron-
ment where the MSC cells are introduced and not to the
cells themselves.
We are convinced that the therapeutic effect which we
observe in our research is caused by the administration
of hADSCs. It is supported by the results of the experi-
ment with blocking human IL-6 using sultiximab. In the
group of mice with hADSCs and sultiximab administra-
tion, we did not observe an influx of M2 macrophages
and increased number of blood vessels.
In the group of mice which were not administered
with sultiximab, we can observe an infiltration of M2
macrophages. Therefore, we can assume that hIL-6 se-
creted by hADSCs is responsible for the infiltration of
the M2 macrophages. If the presence of the macro-
phages was a consequence of the activation of the im-
mune system of the mouse, the infiltration should be
observed irrespectively of blocking hIL-6 and it would
be mainly M1 macrophages. It should be noted that in
our conditions the administered hADSCs live short,
about 14 days, but long enough to trigger the therapeutic
effect. The influence of multiple administrations of MSC
cells on the immune system of the recipient still remains
a separate matter.
Higher efficiency of hADSCs is probably due to the re-
lease of larger amounts of IL-6. However, we cannot ex-
clude that it might be the cause of the activation of
different subtypes of M2 macrophages by hADSC cells
of allograft and xenograft. In the future, we plan to in-
vestigate the participation of M2a and M2b macrophages
in the repair process of damaged tissues with the
utilization of ADSC.
The goal of our therapy was not to replace the dam-
aged muscle tissue with hADSCs which differentiated
into muscle cells. The aim was to activate the mecha-
nisms enabling the repair of the damaged tissue. Our re-
sults confirm that 14 days is a sufficient period to initiate
such mechanisms in mice.
It seems that this solution may be used in clinical
practice: hADSCs initiate the repair process and then die
or are removed by the immune system without any risk
to the recipient. Short retention time (14 days) of
hADSCs in the muscle allows repeated administration of
the cells which may or may not increase the therapeutic
effect. Naturally, we cannot exclude the idea that mul-
tiple usage of hADSC cells can in the end cause an ex-
cessive reaction of the immune system in the organism
of the recipient.
The efficiency of the cells isolation depends on the
quality and origin of the collected tissue. Cells isolated
from fragments of adipose tissue collected from various
donors differed in their morphology and the ability to
multiply in culture (unpublished results). In clinical
practice, it would mean that for a particular group of pa-
tients we would not be able to obtain a sufficient num-
ber of hADSCs for cell therapy. The solution to this
problem may be the hADSCs allograft. Based on our re-
search, it seems possible and relatively safe. It also seems
that stimulation of the cells to increase IL-6 secretion
could improve the therapeutic effect.
Conclusions
In conclusion, the hADSCs introduced into the damaged
tissue secrete interleukin 6. In our opinion, this cytokine
activates macrophages with the M2 phenotype, which
suppress inflammation and activate the process of angio-
genesis and the repair of the damaged muscle.
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